Foundayo Pricing: September 2026

Foundayo self-pay now tops out at $299, down from about $349. Foundayo (orforglipron) is Eli Lilly's once-daily GLP-1 pill, approved April 1, 2026, and its wholesale acquisition cost (WAC), the list price, is $649 a month, although few people pay that. As of September 2, 2026, LillyDirect lists the 0.8 mg starting dose at $149 a month, the 2.5 mg dose also at $149, and the 5.5 mg dose at $199, with the last two marked as temporary cuts through December 31, 2026. The 9 mg dose is $299, and the 14.5 mg and 17.2 mg doses are $299 when refilled within 45 days under the Self-Pay Journey Program. Lilly's April launch put the top tier near $349, so the maintenance price has come down.

All three big PBMs now cover it. A pharmacy benefit manager (PBM) builds the drug list, called a formulary, for employer health plans, and Foundayo is now on all three of the largest ones. Express Scripts and OptumRx covered Foundayo from launch, and CVS Caremark removed its new-to-market block on June 1, 2026, opening a standard formulary that reaches 25 to 30 million people. With commercial coverage, Lilly's savings card brings the copay to as little as $25 a month, although employers still decide whether to include obesity drugs at all.

Medicare covers the pill through the Bridge. The Medicare GLP-1 Bridge launched July 1, 2026, and eligible Part D members pay $50 a month for any Foundayo strength, with a prior authorization (an approval request) filed by their prescriber. CMS extended the program through December 31, 2027 because the BALANCE Model will not launch in Medicare in 2027, and the $50 copay does not count toward the Part D deductible. TrumpRx.gov has a Foundayo page that routes to LillyDirect, but its price table listed no Foundayo price on September 2, 2026. The November 2025 deal set the starting dose of oral GLP-1s at $150 on TrumpRx, and LillyDirect charges $149.

The launch is slower than the Wegovy pill. Fierce Pharma's IQVIA-based tracker counted 19,879 Foundayo prescriptions in week 9, against 159,000 for Novo Nordisk's Wegovy pill in its week 22. Lilly reported $98 million in Foundayo sales for the second quarter on August 5, 2026, its first full quarter, while the Wegovy pill did $496 million in the same period. Lilly said Foundayo prescriptions doubled in a month and that about one in four new oral GLP-1 starts now go to Foundayo, though analysts had expected about $103 million.

For the head-to-head, see Foundayo vs. Oral Wegovy. For Lilly's injectable, see Zepbound Pricing: September 2026. For Medicare rules in detail, see the Medicare GLP-1 Bridge Pricing Guide. For the whole class, see the GLP-1 Drug Pricing Guide: September 2026.